H3 K27M Clinical Trials

2 recruiting

H3 K27M Trials at a Glance

16 actively recruiting trials for h3 k27m are listed on ClinicalTrialsFinder across 6 cities in 25 countries. The largest study group is Phase 1 with 7 trials, with the heaviest enrollment activity in Boston, Chicago, and Columbus. Lead sponsors running h3 k27m studies include Jazz Pharmaceuticals, Nationwide Children's Hospital, and Columbia University.

Browse h3 k27m trials by phase

Treatments under study

About H3 K27M Clinical Trials

Looking for clinical trials for H3 K27M? There are currently 2 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new H3 K27M trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about H3 K27M clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 116 of 16 trials

Recruiting
Phase 2

Study of Ribociclib and Everolimus in HGG and DIPG or Ribociclib and Temozolomide in DHG, H3G34-mutant

Metastatic Brain TumorGlioblastomaGlioblastoma Multiforme+7 more
Nationwide Children's Hospital120 enrolled21 locationsNCT05843253
Recruiting
Phase 3

ONC201 in H3 K27M-mutant Diffuse Glioma Following Radiotherapy (the ACTION Study)

GliomaH3 K27M
Jazz Pharmaceuticals510 enrolled162 locationsNCT05580562
Recruiting

Targeted Pediatric High-Grade Glioma Therapy

Metastatic Brain TumorGlioblastomaGlioblastoma Multiforme+6 more
Nationwide Children's Hospital350 enrolled21 locationsNCT05839379
Recruiting
Phase 1

rHSC-DIPGVax Plus Checkpoint Blockade for the Treatment of Newly Diagnosed DIPG and DMG

Diffuse Intrinsic Pontine GliomaDiffuse Midline Glioma, H3 K27M-Mutant
Ann & Robert H Lurie Children's Hospital of Chicago36 enrolled3 locationsNCT04943848
Recruiting
Phase 3

Biological Medicine for Diffuse Intrinsic Pontine Glioma (DIPG) Eradication 2.0

Diffuse Intrinsic Pontine GliomaDiffuse Midline Glioma, H3K27-alteredDiffuse Midline Glioma, H3 K27M-Mutant
Gustave Roussy, Cancer Campus, Grand Paris433 enrolled50 locationsNCT05476939
Recruiting
Phase 1

FUS Etoposide for DMG

Diffuse Intrinsic Pontine GliomaDiffuse Midline Glioma, H3 K27M-Mutant
Columbia University10 enrolled1 locationNCT05762419
Recruiting
Phase 1

Loc3CAR: Locoregional Delivery of B7-H3-CAR T Cells for Pediatric Patients With Primary CNS Tumors

Central Nervous System NeoplasmsGlioblastomaHigh Grade Glioma+4 more
St. Jude Children's Research Hospital48 enrolled1 locationNCT05835687
Recruiting
Phase 2

Stereotactic Biopsy Split-Course Radiation Therapy in Diffuse Midline Glioma, SPORT-DMG Study

Diffuse Midline Glioma, H3 K27M-Mutant
Mayo Clinic29 enrolled2 locationsNCT05077735
Recruiting
Phase 1

Phase I Study of Oral ONC206 in Recurrent and Rare Primary Central Nervous System Neoplasms

Central Nervous System NeoplasmsGlioblastomaOligodendroglioma+20 more
Jazz Pharmaceuticals102 enrolled1 locationNCT04541082
Recruiting

Observational Study for Assessing Treatment and Outcome of Patients With Primary Brain Tumours Using cIMPACT-NOW and 2021 WHO Classification

Germ Cell TumorGliomaEpendymoma+10 more
European Organisation for Research and Treatment of Cancer - EORTC1,650 enrolled42 locationsNCT05259605
Recruiting
Phase 2

Combination Therapy for the Treatment of Diffuse Midline Gliomas

Recurrent Diffuse Intrinsic Pontine GliomaDiffuse Intrinsic Pontine GliomaWHO Grade III Glioma+3 more
University of California, San Francisco360 enrolled32 locationsNCT05009992
Recruiting
Phase 1Phase 2

Treatment of Relapsed/Refractory Intracranial Glioma in Patients Under 22 Years of Age

Glioblastoma MultiformeOligodendrogliomaDiffuse Intrinsic Pontine Glioma+5 more
University of Miami20 enrolled1 locationNCT05956821
Recruiting

International Diffuse Intrinsic Pontine Glioma (DIPG)/Diffuse Midline Glioma (DMG) Registry and Repository

Diffuse Intrinsic Pontine GliomaDiffuse Midline Glioma, H3 K27M-MutantDiffuse Midline Glioma
Children's Hospital Medical Center, Cincinnati1,500 enrolled1 locationNCT03101813
Recruiting
Phase 2

Study of Olutasidenib and Temozolomide in HGG

Metastatic Brain TumorIDH1 MutationAstrocytoma, Grade IV+16 more
Rigel Pharmaceuticals60 enrolled18 locationsNCT06161974
Recruiting
Phase 1

CD200AR-L and Allogeneic Tumor Lysate Vaccine Immunotherapy for Recurrent HGG and Newly Diagnosed DMG/DIPG in Children and Young Adults

Diffuse Midline Glioma, H3 K27M-MutantRecurrent High Grade Glioma
OX2 Therapeutics24 enrolled1 locationNCT06305910
Recruiting
Phase 1

CAR T Cells to Target GD2 for DMG

Diffuse Midline Glioma, H3 K27M-Mutant
University College, London12 enrolled1 locationNCT05544526